Developing Novel Drug Candidates

Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile.

Our goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.

We are listed on the AIM market of the London Stock Exchange (symbol ‘SUMM’) and the NASDAQ Global Market (symbol ‘SMMT’).  Further information is available in our dedicated Investor Relations section.


2017 AGM

The 2017 AGM will be held on 18 July 2017.

Click for further details and to download the 2017 Annual Report and Notice of AGM.


Share Price

175.00p 0.00
at 01:14pm GMT 22 Jun 2017

$11.43 0.35
at 01:24pm ET 22 Jun 2017